Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initumab-based first-line treatment for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2100041919Phase 2Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of initumab, pyrotinib, oxaliplatin, capecitabine and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
initumabpyrotiniboxaliplatincapecitabinepaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100041919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041919.